Farnesoid X receptor (FXR) activation and FXR genetic variation in inflammatory bowel disease. - Wikidata - wikimedia - TriplyDB

Farnesoid X receptor (FXR) activation and FXR genetic variation in inflammatory bowel disease.

Farnesoid X receptor (FXR) activation and FXR genetic variation in inflammatory bowel disease.

http://www.wikidata.org/entity/Q34009566

about

Pregnane X receptor as a target for treatment of inflammatory bowel disorders Bile acid signaling in metabolic disease and drug therapy The bile acid sensor FXR is required for immune-regulatory activities of TLR-9 in intestinal inflammation Commensal bacteria at the interface of host metabolism and the immune system.Microbiota regulate intestinal epithelial gene expression by suppressing the transcription factor Hepatocyte nuclear factor 4 alpha Association of genetic variation in the NR1H4 gene, encoding the nuclear bile acid receptor FXR, with inflammatory bowel disease.Pharmacological activation of the bile acid nuclear farnesoid X receptor is feasible in patients with quiescent Crohn's colitis.Impact of global Fxr deficiency on experimental acute pancreatitis and genetic variation in the FXR locus in human acute pancreatitis.Bacterial bile metabolising gene abundance in Crohn's, ulcerative colitis and type 2 diabetes metagenomes.Systematic review: bile acids and intestinal inflammation-luminal aggressors or regulators of mucosal defence?FXR and liver carcinogenesis Structural Investigation for Optimization of Anthranilic Acid Derivatives as Partial FXR Agonists by in Silico Approaches.The Gut Microbiota as a Therapeutic Target in IBD and Metabolic Disease: A Role for the Bile Acid Receptors FXR and TGR5.The Gdac1 locus modifies spontaneous and Salmonella-induced colitis in mice deficient in either Gpx2 or Gpx1 gene.The impact of farnesoid X receptor activation on intestinal permeability in inflammatory bowel disease.Altered enterohepatic circulation of bile acids in Crohn's disease and their clinical significance: a new perspective.Characterizing ligands for farnesoid X receptor--available in vitro test systems for farnesoid X receptor modulator development.Systems biology approaches for inflammatory bowel disease: emphasis on gut microbial metabolism.Bile acid malabsorption in inflammatory bowel disease.Farnesoid x receptor in human metabolism and disease: the interplay between gene polymorphisms, clinical phenotypes and disease susceptibility.Bacterial metabolites directly modulate farnesoid X receptor activity.The expanding role of the bile acid receptor farnesoid X in the intestine and its potential clinical implications.Understanding the Holobiont: How Microbial Metabolites Affect Human Health and Shape the Immune System.Trimethylamine-N-oxide: A Novel Biomarker for the Identification of Inflammatory Bowel Disease.Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis.The farnesoid-X-receptor in myeloid cells controls CNS autoimmunity in an IL-10-dependent fashion.Bile acid malabsorption deactivates pregnane X receptor in patients with Crohn's disease.Diarrhea in Crohn’s disease: investigating the role of the ileal hormone fibroblast growth factor 19.Farnesoid X Receptor Expression in Microscopic Colitis: A Potential Role in Disease Etiopathogenesis.Alterations in Enterohepatic Fgf15 Signaling and Changes in Bile Acid Composition Depend on Localization of Murine Intestinal Inflammation.Farnesoid X receptor expression is decreased in colonic mucosa of patients with primary sclerosing cholangitis and colitis-associated neoplasia.Role of bile acids in inflammatory bowel disease.

P2860

Q26998347-2B4FCF1A-0F1F-4474-9216-7E42D7B8CA55 Q28244875-BE0431C2-ED65-40B1-8728-FDE3DCCF66E6 Q28585275-90ECB0B6-E162-4669-85AD-8BF005A3C49E Q33578547-260C5EF5-D4D3-4921-8892-B05E48A0E785 Q33865173-AD70A565-73E5-4576-9CF0-6F1EC8B56628 Q34396606-2743E156-40E8-48D1-9AE1-89967477CEC1 Q34493836-BAAA4F29-80F4-42D9-8ED4-45A0506D2D52 Q34627935-EABBDF45-38A2-424C-AD3D-9E15F38DF7B5 Q34724632-59216FE2-9D31-41E5-8E1F-6753C536B0BE Q35724871-82724EF2-B133-4138-997A-992CDD3DC55E Q36063712-748FBBEC-A73D-418D-8F14-AEBA06DFAA4F Q36847145-65122563-48D3-4A80-84A4-F147B4736A37 Q37255981-D127637A-486B-4A9D-8DA8-B54A4A4DF4A5 Q37419561-70FD3D16-4139-4BF1-AC50-C4BC1A114194 Q38044907-D0DD6767-62A1-4454-BAF6-F8EC293EA80F Q38069608-8BE8582B-E712-41BC-9D32-266BCE4B7E13 Q38164798-9C30B1CF-C7B8-44B5-BA4B-5585BD9297B2 Q38230162-CD339C50-27B2-4ADF-87FF-5F9A97545106 Q38253467-335AA788-0355-4A51-9E41-678B8D7FED49 Q38305576-0B8111B7-2B07-4D5B-AF18-4DC2A19158E0 Q38816859-A779CD0A-35E1-4500-AB76-A3A13A7EFEC3 Q38967650-061C962A-81D7-46A3-8714-1A43AED5C9D4 Q39381331-BD21079F-606A-435E-81C1-37E3209AD560 Q40752459-8BFD02C0-9B85-4D37-8D34-B92B0E5B7F77 Q47668921-A1952A6A-B813-4762-ACAA-AF99F883B8C0 Q50788241-FF3D798F-6EB4-4904-89F1-0B3830B9A94D Q51076088-34B73F8C-BF7E-4EC5-9F8C-A2FED8EBD224 Q51310817-9F8874CA-18CF-4C28-9275-904FE5763C04 Q51750234-F250AA11-06E3-4AF3-A64E-7F920D2BCD72 Q51829714-369D1615-E51B-4F48-9A8C-9B179011C9F4 Q54274429-5041E261-7841-4F0C-BFCF-B7C8FEF6632B Q54943140-A97CC8F0-786C-414F-8CE2-5BEF75C01D45

P2860

Farnesoid X receptor (FXR) activation and FXR genetic variation in inflammatory bowel disease.

http://www.wikidata.org/entity/Q34009566

description

2011 nî lūn-bûn

@nan

2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Farnesoid X receptor (FXR) act ...... in inflammatory bowel disease.

@ast

Farnesoid X receptor (FXR) act ...... in inflammatory bowel disease.

@en

type

label

Farnesoid X receptor (FXR) act ...... in inflammatory bowel disease.

@ast

Farnesoid X receptor (FXR) act ...... in inflammatory bowel disease.

@en

prefLabel

Farnesoid X receptor (FXR) act ...... in inflammatory bowel disease.

@ast

Farnesoid X receptor (FXR) act ...... in inflammatory bowel disease.

@en

P1433

Q34009566-B89EC02B-6965-48A8-8AD3-B37955A40957

P1476

Q34009566-96E0F8C0-2037-4716-802D-7064DEA46436

P2093

Q34009566-0163F829-0C69-4667-8FD1-4380939FC5BA

Q34009566-0D04DA79-413C-4A98-8ACE-2EA5393D8A02

Q34009566-20B28B8D-7C9A-4F7B-9B51-A2CC3EAC00FD

Q34009566-31B75B5D-82A4-4441-91F8-DA38403C3357

Q34009566-324036E4-5D71-4AFB-B28A-67370C31B67E

Q34009566-4386CE41-5AE2-4656-9456-B91F4B1DB3A1

Q34009566-4E0B5423-F711-4D60-88C4-A31412C4E868

Q34009566-60FA7F5D-E296-438A-95B0-C26D8DE41EC0

Q34009566-6335C0AF-8B41-406E-919E-E025B7176523

Q34009566-6ACEFE93-17FA-45B7-A5B8-735C95153A18

P2860

Q34009566-0AB5A248-9F8C-4F46-A3A3-7AC8B3D9A274

Q34009566-0B635467-23D1-40E4-B5E3-D12D0BB35467

Q34009566-0C944D9D-D730-4DA1-960E-EBEF020F4E50

Q34009566-165A37D5-0D09-421E-AEF0-45765E80AF21

Q34009566-2C46A6F2-30E8-4289-89C2-0B6F1E782D9B

Q34009566-4C277C19-3512-4DE8-B267-940303FA1CB5

Q34009566-4DDBD9B0-A203-46C2-9830-784C199E0644

Q34009566-515FC2D7-82A4-4042-B953-9D14700F960A

Q34009566-54BCA787-5689-41D6-894C-B1A6B1422393

Q34009566-554BDB30-0D64-49F8-A704-AA7970CA80BB

P304

Q34009566-22F246D4-E8BB-424F-AAC2-23F4609CD72C

P31

Q34009566-7C4DB21C-26CA-4A4D-A63E-F1BFCF89AF18

P356

Q34009566-FC813193-E5CE-4C62-BA5A-018F62463C65

P407

Q34009566-826E71C7-9596-41AB-A5DB-08A168CCDD7C

P433

Q34009566-1BBE7223-3237-468E-A080-1B40E7574F80

P478

Q34009566-7EAD782F-A889-4378-A04C-48728E5D59DC

P50

Q34009566-4E014A7C-E7A7-467C-BBCE-26010E036290

P577

Q34009566-B58FBFEC-7EA3-43C6-8D69-490E7C6EA688

P5875

Q34009566-2351AD11-41C1-41C2-8226-93919F890D03

P698

Q34009566-866FA32D-105F-4F14-A950-430ECBAE5BE4

P921

Q34009566-3044069D-9BC2-4A85-B818-9AE8DFCCDFF8

P932

Q34009566-1ABD2456-B986-4C23-8364-CD1A72C72A71

P356

JOURNAL.PONE.0023745

P1433

P1476

Farnesoid X receptor (FXR) act ...... in inflammatory bowel disease.

@en

P2093

Adriaan A van Bodegraven

http://www.w3.org/2001/XMLSchema#string

Bas Oldenburg

http://www.w3.org/2001/XMLSchema#string

C Janneke van der Woude

http://www.w3.org/2001/XMLSchema#string

Daan W Hommes

http://www.w3.org/2001/XMLSchema#string

Dirk J de Jong

http://www.w3.org/2001/XMLSchema#string

Dutch Initiative on Crohn, Colitis (ICC)

http://www.w3.org/2001/XMLSchema#string

Gerard Dijkstra

http://www.w3.org/2001/XMLSchema#string

Hein W Verspaget

http://www.w3.org/2001/XMLSchema#string

J Bart A Crusius

http://www.w3.org/2001/XMLSchema#string

Janneke M Stapelbroek

http://www.w3.org/2001/XMLSchema#string

P2860

Inflammatory Bowel Disease

Mechanisms of Disease: pathogenesis of Crohn's disease and ulcerative colitis

Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes

Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci

The nuclear receptor superfamily: the second decade

Haploview: analysis and visualization of LD and haplotype maps

Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease

The bile acid receptor FXR is a modulator of intestinal innate immunity

Genetic variation in myosin IXB is associated with ulcerative colitis

Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor

P304

e23745

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0023745

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-08-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51614964

http://www.w3.org/2001/XMLSchema#string

P698

21887309

http://www.w3.org/2001/XMLSchema#string

P921

inflammatory bowel diseases

P932

3161760

http://www.w3.org/2001/XMLSchema#string